Effects of misdiagnosis in input data on the identification of differential expression genes in incipient alzheimer patients

In Silico Biology

Volumn 8, Issue 5-6, 2008, Pages 545-554

  Joseph, Sandeep ^a   Robbins, Kelly ^a   Zhang, Wensheng ^a   Rekaya, Romdhane ^a  

^a UNIVERSITY OF GEORGIA   (United States)

Author keywords

Alzheimer's Disease; Gene expression; Mini Mental Sate Examination (MMSE) and Neurofibrillary Tangles Score (NFT); Misclassification algorithm; Mixed model analysis

Indexed keywords

ALZHEIMER DISEASE; DIAGNOSTIC ERRORS; GENE EXPRESSION REGULATION; HUMANS;

EID: 58149387579     PISSN: 13866338     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (49)

1. Auld, D. S., Kornecook, T. J., Bastianetto, S. and Quirion, R. (2002). Alzheimer's disease and the basal forebrain cholinergic system: relations to β-amyloid peptides, cognition and treatment strategies. Prog. Neurobiol. 68, 209-245.
2. Holmes, C. (2002). Genotype and phenotype in Alzheimer's disease. Br. J. Psychiatry 180, 131-134.
3. Tanzi, R. E. and Bertram, L. (2001). New frontier's of Alzheimer's disease genetics. Neuron 32, 181-184.
4. Noble, W., Olm, V., Takata, K., Casey, E., Mary, O., Meyerson, J., Gaynor, K., LaFrancois, J., Wang, L., Kondo, T., Davies, P., Burns, M., Veeranna, Nixon, R., Dickson, D., Matsuoka, Y., Ahlijanian, M., Lau, L. F. and Duff, K. (2003). Cdk5 is a key factor in tau aggregation and tangle formation in vivo. Neuron 38, 555-565.
5. Ahsenov, M. Y., Aksenova, M. V., Butterfield, D. A., Geddes, J. W. and Markesbery, W. R. (2001) Protein oxidation in the brain in Alzheimer's disease. Neuroscience 103, 373-383.
6. Casserly, I. and Topol, E. (2004). Convergence of atherosclerosis and Alzheimer's disease: Inflammation, cholesterol, and misfolded proteins. Lancet 363, 1139-1146.
7. Forman, M. S., Lee, V. M. and Trojanowski, J. Q. (2003). 'Unfolding'Pathways in neurodegenerative disease. Trends Neurosci. 8 407-410.
8. Nixon, R. A., Saito, K. I., Grynspan, F., Griffin,W. R., Katayama, S., Honda, T., Mohan, P. S., Shea, T. B. and Beermann, M. (1994). Calcium-activated neutral proteinase (calpain) system in aging and Alzheimer's disease. Ann. N. Y. Acad. Sci. 747, 77-91.
9. Morris, J. C. and Price, A. L. (2001). Pathological correlates of nondemented aging, mild cognitive impairment and early stage Alzheimer's disease. J. Mol. Neurosci. 17, 101-118.
10. Yao, P. J., Morsch, R., Callahan, L. M. and Coleman, P. D. (1999). Changes in synaptic expression of clathrin assembly protein AP180 in Alzheimer's disease analysed by immunohistochemistry. Neuroscience 94 389-394.
11. Lukiw, W. J. and Bazan, N. G. (1998). Strong nuclear factor-κB-DNA binding parallels cycloxygenase-2 gene transcription in aging and in sporadic Alzheimer's disease superior temporal lobe neocortex. J. Neurosci. Res. 53, 583-92.
12. Galasko, D., Klauber, M. R., Hofstetter, C. R., Salmon, D. P., Lasker, B. and Thal, L. J. (1990) The Mini-Mental State Examination in the early diagnosis of Alzheimer's disease. Arch. Neurol. 47, 49-52.
13. Haroutunian, V., Purohit, D. P., Perl, D. P., Marin, D., Khan, K., Lantz, M., Davis, K. L. and, Mohs, R. C. (1999). Neurofibrillary tangles in nondemented elderly subjects and mild Alzheimer disease. Arch. Neurol. 56, 713-718.
14. Alexander, G. E., Chen, K., Pietrini, P., Rapoport, S. I. and Reiman, E. M. (2002). Longitudinal PET Evaluation of Cerebral Metabolic Decline in Dementia: A Potential Outcome Measure in Alzheimer's Disease Treatment Studies. Am. J. Psychiatry 159, 738-745.
15. Johnson, K. A., Jones, K., Holman, B. L., Becker, J. A., Spiers, P. A., Satlin, A. and Albert, M. S. (1998) Preclinical prediction of Alzheimer's disease using SPECT. Neurology. 50, 1563-1571.
16. Killiany, R. J., Gomez-Isla, T., Moss, M., Kikinis, R., Sandor, T., Jolesz, F., Tanzi, R., Jones, K., Hyman, B. T. and Albert, M. S. (2000). Use of structural magnetic resonance imaging to predict who will get Alzheimer's disease. Ann. Neurol. 47, 430-439.
17. Ramaswamy, S., Tamayo, P., Rifkin, R., Mukherjee, S., Yeang, C.-H., Angelo, M., Ladd, C., Reich, M., Latulippe, E., Mesirov, J. p., Poggio, T., Gerald,W., Loda, M., Lander, E. S. and Golub, T. R. (2001). Multiclass cancer diagnosis using tumor gene expression signatures. Proc. Natl. Acad. Sci. USA 98, 15149-15154.
18. Dudoit, S., Fridlyand, J. and Speed, T. P. (2002). Comparison of discrimination methods for classification of tumors using gene expression data. J. Am. Stat. Assoc. 97, 77-87.
19. Golub, T. R., Slonim, D. K., Tamayo, P., Huard, C., Gassenbeek, M., Mesirov, P., Loh, M. L., Downing, J. R., Caligiuri, M. A., Bloomfield, C. D. and Lander, E. S. (1999). Molecular classification of cancer: class discovery and class prediction by gene expression monitoring. Science 286, 531-537.
20. West, M., Blanchette, C., Dressman, H., Huang, E., Ishida, S., Spang, R., Zuzan, H., Olson, J. A. Jr., Marks, J. R. and Nevins, J. R. (2001). Predicting the clinical status of human breast cancer by using gene expression profiles. Proc. Natl. Acad. Sci. USA 98, 11462-11467.
21. Ricciarelli, R., d'Abramo, C., Massone, S., Marinari, U., Pronzato, M. and Tabaton, M. (2004). Microarray analysis in Alzheimer's disease and normal aging. IUBMB Life 56, 349-354.
22. Li, T., Zhang, C. and Ogihara, M. (2004). A comparative study of feature selection and multiclass classification methods for tissue classification based on gene expression. Bioinformatics 20, 2429-2437
23. Zhang, W., Rekaya, R. and Bertrand, K. (2006). A method for predicting disease subtypes in presence of misclassification among training samples using gene expression: Application to human breast cancer. Bioinformatics 22, 317-325.
24. Robbins, K., Joseph, S., Zhang, W., Rekaya, R. and Bertrand, J. K. (2006). Classification of incipient Alzheimer patients using gene expression data: Dealing with potential misdiagnosis. Online J. Bioinformatics 7, 22-31.
25. Blalock, E. M., Geddes, J. W., Chen, K. C., Porter, N. M., Markesbery, W. R. and Landfield, P. W. (2004). Incipient Alzheimer's disease: microarray correlation analyses reveal major transcriptional and tumor suppressor responses. Proc. Natl. Acad. Sci. USA 101, 2173-2178.
26. Chu, T.-M.,Weir, B. and Wolfinger, R. (2002). A systematic statistical linear modeling approach to oligonucleotide array experiments. Math. Biosci. 176, 35-51.
27. Irizarry, R. A., Bolstad, B. M., Collin, F., Cope, L. M., Hobbs, B. and Speed, T. P. (2003). Summaries of Affymetrix GeneChip probe level data. Nucleic Acids Res. 31, e15.
28. Wolfinger, R. D., Gibson, G.,Wolfinger, E. D., Bennett, L., Hamadeh, H., Bushel, P., Afshari, C. and Paules, R. S. (2001). Assessing gene significance from cDNA microarray expression data via mixed models. J. Comput. Biol. 8, 625-637.
29. Littell, R. C., Milliken, G. A., Stroup, W. W. and Wolfinger, R. D. (1996). SAS system for mixed models, SAS Institute Inc., Cary, NC.
30. Hochberg, Y. and Benjamini, Y. (1995). Controlling the false discovery rate: A practical and powerful approach to multiple testing. J. R. Stat. Soc. Ser. B Stat. Methodol. 57, 289-300.
31. Masliah, E., Mallory, M., Alford, M., DeTeresa, R., Hansen, L. A., McKeel, D. W. Jr. and Morris, J. C. (2001). Altered expression of synaptic proteins occurs early during progression of Alzheimer's disease. Neurology 56, 127-129.
32. Heinonen, O., Soininen, H., Sorvari, H., Kosunen, O., Paljärvi, L., Koivisto, E. and Riekkinen, P. J. Sr. (1995). Loss of synaptophysin-like immunoreactivity in the hippocampal formation is an early phenomenon in Alzheimer's disease. Neuroscience 64, 375-384.
33. Davidsson, P., Jahn, R., Bergquist, J., Ekman, R. and Blennow, K. (1996). Synaptotagmin, a synaptic vesicle protein, is present in human cerebrospinal fluid: A new biochemical marker for synaptic pathology in Alzheimer disease? Mol. Chem. Neuropathol. 27, 195-210.
34. Masliah, E., Mallory, M., Hansen, L., DeTeresa, R., Alford, M. and Terry, R. (1994). Synaptic and neuritic alterations during the progression of Alzheimer's disease. Neurosci. Lett. 174, 67-72.
35. Callahan, L. M., Vaules, W. A. and Coleman, P. D. (1999). Quantitative decrease in synaptophysin message expression and increase in cathepsin D message expression in Alzheimer disease neurons containing neurofibrillary tangles. J. Neuropathol. Exp. Neurol. 58, 275-287.
36. olzl, J., Mahata, S. K., Jellinger, K. A. and Marksteiner, J. (2004). Chromogranin peptides in Alzheimer's disease. Exp. Gerontol. 39, 101-113.
37. Sze, C.-I., Bi, H., Kleinschmidt-DeMasters, B. K., Filley, C. M. and Martin, L. J. (2000). Selective regional loss of exocytotic presynaptic vesicle proteins in Alzheimer's disease brains. J. Neurol. Sci. 175 81-90.
38. Greber, S., Lubec, G., Cairns, N. and Fountoulakis, M. (1999). Decreased levels of synaptosomal associated protein 25 in the brain of patients with Down syndrome and Alzheimer's disease. Electrophoresis 20, 928-934.
39. Clinton, J., Blackman, S. E., Royston, M. C. and Roberts, G. W. (1994). Differential synaptic loss in the cortex in Alzheimer's disease: A study using archival material. Neuroreport 5, 497-500.
40. Masliah, E., Fagan, A. M., Terry, R. D., DeTeresa, R., Mallory, M. and Gage, F. H. (1991). Reactive synaptogenesis assessed by synaptophysin immunoreactivity is associated with GAP-43 in the dentate gyrus of the adult rat. Exp. Neurol. 113, 131-142.
41. Mikkonen, M., Alafuzoff, I., Tapiola, T., Soininen, H. and Miettinen, R. (1999). Subfield- and layer-specific changes in parvalbumin, calretinin and calbindin-D28K immunoreactivity in the entorhinal cortex in Alzheimer's disease. Neuroscience 92, 515-532.
42. Mazurek, M. F. and Beal, M. F. (1991) Cholecystokinin and somatostatin in Alzheimer's disease postmortem cerebral cortex. Neurology 41, 716-719.
43. Armstrong, D. M., Sheffield, R., Mishizen-Eberz, A. J., Carter, T. L., Rissman, R. A., Mizukami, K. and Ikonomovic, M. D. (2003). Plasticity of glutamate and GABAA receptors in the hippocampus of patients with Alzheimer's disease. Cell. Mol. Neurobiol. 23, 491-505.
44. Ramírez, B. G., Blázquez, C., Gómez del Pulgar, T., Guzmán, M. and de Ceballos, M. L. (2005). Prevention of Alzheimer's disease pathology by cannabinoids: Neuroprotection mediated by blockade of microglial activation. J. Neurosci. 25, 1904-1913.
45. Mori, N., Stein, R., Sigmund, O. and Anderson, D. J. (1990). A cell type-preferred silencer element that controls the neural-specific expression of the SCG10 gene. Neuron 4, 583-594.
46. Iwai, A., Yoshimoto, M., Masliah, E. and Saitoh, T. (1995). Non-A beta component of Alzheimer's disease amyloid (NAC) is amyloidogenic. Biochemistry 34, 10139-10145.
47. Masliah, E. (1998) Mechanisms of synaptic pathology in Alzheimer's disease. J. Neural Transm. Suppl. 53, 147-158.
48. Choi, J., Levey, A. I., Weintraub, S. T., Rees, H. D., Gearing, M., Chin, L.-S. and Li, L. (2004). Oxidative modifications and down-regulation of ubiquitin carboxyl-terminal hydrolase L1 associated with idiopathic Parkinson's and Alzheimer's diseases. J. Biol. Chem. 279, 13256-13264.
49. Zhu, X., Sun, Z., Lee, H.-g., Siedlak, S. L, Perry, G. and Smith, M. A. (2003). Distribution, levels, and activation of MEK1 in Alzheimer's disease. J. Neurochem. 86, 136-142.